» Articles » PMID: 23349877

Toll-like Receptor Ligands Induce Expression of the Costimulatory Molecule CD155 on Antigen-presenting Cells

Overview
Journal PLoS One
Date 2013 Jan 26
PMID 23349877
Citations 38
Authors
Affiliations
Soon will be listed here.
Abstract

Genotoxic stress and RAS induce the expression of CD155, a ligand for the immune receptors DNAM-1, CD96 and TIGIT. Here we show that antigen-presenting cells upregulate CD155 expression in response to Toll-like receptor activation. Induction of CD155 by Toll-like receptors depended on MYD88, TRIF and NF-κB. In addition, IRF3, but not IRF7, modulated CD155 upregulation in response to TLR3 signals. Immunization of CD155-deficient mice with OVA and the TLR9 agonist CpG resulted in increased OVA-specific IgG2a/c titers when compared to wild type mice. Splenocytes of immunized CD155-deficient mice secreted lower levels of IL-4 and fewer IL-4 and GATA-3 expressing CD4(+) T cells were present in the spleen of Cd155(-/-) mice. Our data suggest that CD155 regulates T(h)2 differentiation. Targeting of CD155 in immunization protocols using peptides may represent a promising new approach to boost protective humoral immunity in viral vaccines.

Citing Articles

SOCS1 Inhibits IL-6-Induced CD155 Overexpression in Lung Adenocarcinoma.

Marroquin-Mucino M, Benito-Lopez J, Perez-Medina M, Aguilar-Cazares D, Galicia-Velasco M, Chavez-Dominguez R Int J Mol Sci. 2024; 25(22).

PMID: 39596207 PMC: 11595078. DOI: 10.3390/ijms252212141.


Revisiting T-cell adhesion molecules as potential targets for cancer immunotherapy: CD226 and CD2.

Jo Y, Sim H, Yun B, Park Y, Jin H Exp Mol Med. 2024; 56(10):2113-2126.

PMID: 39349829 PMC: 11541569. DOI: 10.1038/s12276-024-01317-9.


Dysregulation of DNAM-1-Mediated NK Cell Anti-Cancer Responses in the Tumor Microenvironment.

Paolini R, Molfetta R Cancers (Basel). 2023; 15(18).

PMID: 37760586 PMC: 10527063. DOI: 10.3390/cancers15184616.


Microbiota-dependent regulation of costimulatory and coinhibitory pathways via innate immune sensors and implications for immunotherapy.

Park J, Gazzaniga F, Kasper D, Sharpe A Exp Mol Med. 2023; 55(9):1913-1921.

PMID: 37696895 PMC: 10545783. DOI: 10.1038/s12276-023-01075-0.


CD155 and Its Receptors as Targets for Cancer Therapy.

Paolini R, Molfetta R Int J Mol Sci. 2023; 24(16).

PMID: 37629138 PMC: 10455395. DOI: 10.3390/ijms241612958.


References
1.
Bottino C, Castriconi R, Pende D, Rivera P, Nanni M, Carnemolla B . Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. J Exp Med. 2003; 198(4):557-67. PMC: 2194180. DOI: 10.1084/jem.20030788. View

2.
Sasaki T, Gan E, Wakeham A, Kornbluth S, Mak T, Okada H . HLA-B-associated transcript 3 (Bat3)/Scythe is essential for p300-mediated acetylation of p53. Genes Dev. 2007; 21(7):848-61. PMC: 1838535. DOI: 10.1101/gad.1534107. View

3.
Seth S, Maier M, Qiu Q, Ravens I, Kremmer E, Forster R . The murine pan T cell marker CD96 is an adhesion receptor for CD155 and nectin-1. Biochem Biophys Res Commun. 2007; 364(4):959-65. DOI: 10.1016/j.bbrc.2007.10.102. View

4.
Akira S, Takeda K, Kaisho T . Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol. 2001; 2(8):675-80. DOI: 10.1038/90609. View

5.
Schmitz F, Mages J, Heit A, Lang R, Wagner H . Transcriptional activation induced in macrophages by Toll-like receptor (TLR) ligands: from expression profiling to a model of TLR signaling. Eur J Immunol. 2004; 34(10):2863-73. DOI: 10.1002/eji.200425228. View